Marc Villecroze (President), Director of Participations of Viveris Management, management company of the innovation mutual fund Innoveris.
Francois Lombard (Vice-President), Managing Director of Turenne Capital Partners, an independent investment company created in 1999 with 2 Associates, which manages a 200 M€ fund invested in 48 companies.
Michel Delaage, Ph.D., co-founded the company and served as CSO until November 2002 when he retired. Michel Delaage was a co-founder of Immunotech where he served as Scientific Director. Currently he is co-founder and member of the supervisory board of InoDiaG and TxCell.
Patrick Cozzone, Ph.D., is Professor of Biophysics at the Faculty of Medicine in Marseille and, since 1998, a member of the Academic Institute of France. He holds an MBA from the University of Chicago Graduate School of Business (USA).
SGAM Alternative Investments represented by Béatrice Llirbat, M.D., Ph.D., Partner at SGAM Alternative Investments (SGAM AI), a wholly-owned subsidiary of Société Générale Asset Management.
Viveris Management represented by Marie-Stéphane de Cérou, Ph.D, life science investment director for Viveris Management, management company of the innovation mutual fund Innoveris.
OTC Asset Management, represented by Paul-Henry Schmelck, M.D., Partner at OTC Asset Management, an independent investment company created in 2002 and managing funds of more than 250 M€.
Blue Medical Investments (BMI) represented by Bernard Majoie, Pharmacist, Ph.D., Partner at Blue Medical and former CEO of Fournier Pharmaceutical Group.
Sandrine Cailleteau, Senior Vice President, head of healthcare practice, at Michel Dyens & Co, a leading independent investment banking firm focused on mergers and acquisitions.
Invitee:
Antoine Béret, co-founded the company and served as CEO until June 2008 when he retired. He was previously CEO of Immunotech, a profitable French biotech now part of Beckman Coulter